Research and Clinical Trials

Brief Description  
About 10% of ovarian cancer patients have an inherited defect in the BRCA1 or the BRCA2 genes. It is believed that patients with these inherited gene defects are particularly sensitive to PARP inhibitors. Patients on this study will take Veliparib, a PARP inhibitor, by mouth twice daily until their disease worsens or unacceptable side effects occur.
Who may be Eligible  
Histologically confirmed: -Epithelial ovarian cancer -Fallopian tube cancer -Primary peritoneal carcinoma Received at least one prior platinum-based chemotherapy regimine; are allowed to have received up to two additional cytotoxic regimens Have a germline mutation in BRCA1 or BRCA2 (confirmation required via Myraid test report) Measurable disease on CT scan or MRI (at least 1 solid lesion at least 1 cm or larger) Adequate blood counts, kidney and liver function No other prior invasive malignancy in past 5 years; may have had localized breast cancer with adjuvant chemotherapy as long as the treatment was completed more than three years prior Ability to swallow pills and be free of signs and symptoms of gastrointestional obstruction No active seizures within last 12 months No pregnant
IRB Number  
Principal Investigator  
Higgins, Robert

For More Information, Contact  Sarah  , Norek
Phone:  (704) 355-1520  Fax:  (704) 355-9897  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive #600 Charlotte, NC 28204